Novanta (NOVT) Q2 2025: Bookings Jump 10% as Design Wins Accelerate Physical AI and Medtech Pipeline
Novanta’s Q2 2025 call surfaced a decisive pivot toward high-growth markets, with new product revenue up sharply and bookings momentum supporting a robust innovation pipeline. Leadership’s focus on advanced surgery, robotics, and physical AI applications is translating into tangible design wins and a strengthening backlog, even as legacy segments face trade and funding headwinds. With cost actions and regional manufacturing underway, the company is positioning for margin resilience and scalable growth into 2026 and beyond.
Summary
- Innovation Pipeline Drives Visibility: New product launches and 150% design win growth are reshaping Novanta’s end-market mix.
- Physical AI and Medtech Outperform: Advanced surgery and robotics segments are capturing secular tailwinds and sticky OEM relationships.
- Cost Actions and Regionalization Set Foundation: Tariff mitigation and manufacturing shifts are key levers for future margin expansion.
Performance Analysis
Novanta’s Q2 results underscored a business in transition, with reported revenue of $241 million and a vitality index (share of sales from products launched within the last five years) climbing to 21%. New product revenue surged over 50% year over year, and customer orders rose 10%, indicating broadening demand visibility. Double-digit growth in advanced surgery and robotics offset declines in legacy industrial and precision medicine segments, where trade disruptions and weak funding persisted.
Gross margin held steady at 46% despite $4 million in year-to-date tariff headwinds, reflecting the company’s ongoing mitigation strategies and cost discipline. Adjusted EBITDA margin landed at 22%. Operating cash flow was pressured by inventory and tax timing, but management expects a rebound in the second half as trade impacts normalize and working capital stabilizes. Segment performance was mixed: automation enabling technology revenue grew 4% year over year, while medical solutions was flat, with advanced surgery up 17% and precision medicine down 13%.
- Bookings Momentum: Book-to-bill ratio of 1.02 and sequential order growth signal improving backlog and customer confidence.
- Tariff and Trade Friction: Tariff costs and China trade uncertainty remain a drag, but regional manufacturing and “China for China” strategies are mitigating risk.
- Cash Flow Dynamics: Temporary working capital build and acquisition costs weighed on Q2 cash conversion, but normalization is expected in Q3.
Overall, the quarter validated Novanta’s pivot toward innovation-led growth, even as legacy headwinds and macro volatility temper the pace of near-term expansion.
Executive Commentary
"Customer orders grew 10% year over year and 20% sequentially, reflecting a strengthening outlook. We also saw significant design win activity grow more than 150% year over year... Our long-term growth strategy remains focused on winning in markets with long-term secular tailwinds, such as precision and AI-driven robotics and automation, advancement of the invasive and robotic surgery, and precision medicine."
Matthias Glastra, Chair and Chief Executive Officer
"Adjusted gross margins were down year over year, but flat sequentially and in line with our expectations despite the increased cost of tariffs... We expect cash flow conversion rates to return closer to historical averages in the third quarter."
Robert Buckley, Chief Financial Officer
Strategic Positioning
1. Physical AI and Robotics as Growth Engine
Novanta is targeting physical AI, defined as robotics and automation systems that integrate sensing, actuation, and software for real-world tasks, as a multi-year, billion-dollar market opportunity. The company secured a $50 million contract with a leading warehouse robotics OEM, and expects sales into physical AI applications to double in 2026 and again in 2027. Proprietary servo drives and haptic sensing, enabling robotic “touch” and safe movement, are at the core of this competitive advantage.
2. Advanced Surgery and Medical Consumables Expansion
Advanced surgery posted double-digit growth, driven by new products in surgical robotics and smoke evacuation, benefiting from regulatory and procedural tailwinds. Medical consumables, recurring-use components that drive stickier revenue, now comprise 15% of sales and are growing at a double-digit pace. Recent design wins with major OEMs for insufflator devices and next-gen pumps further extend the company’s reach in minimally invasive surgery.
3. Regional Manufacturing and Tariff Response
Trade friction, especially US-China tariffs, is prompting a regional manufacturing shift. Novanta’s “China for China” strategy (manufacturing in China for the local market) helped drive 15% China sales growth, even as US exports to China remain muted. Cost reduction and regionalization initiatives are expected to structurally expand margins and reduce volatility from global trade dynamics.
4. Portfolio Evolution via M&A and Software Integration
The Keyon acquisition, focused on RFID and AI-enhanced inventory management, is outperforming expectations and fills a software gap for deeper hospital penetration. Management signaled a robust M&A pipeline, with a recently expanded credit facility providing up to $1.4 billion in borrowing capacity to accelerate portfolio evolution toward higher-growth, recurring, and software-rich businesses.
5. Life Sciences and Precision Medicine Technology Shift
Precision medicine sales declined, but the business is pivoting to new technologies such as RFID and machine vision, with a new partnership in embedded vision for OEM life science customers. Management expects sequential improvement as the product mix shifts and legacy headwinds moderate.
Key Considerations
Novanta’s Q2 call highlighted a business at an inflection point, balancing legacy headwinds with robust innovation-led growth and aggressive cost actions. The company’s strategic bets on physical AI, advanced surgery, and recurring consumables are yielding tangible results, but execution on regionalization and M&A will be critical to sustaining momentum.
Key Considerations:
- Design Win Velocity: 150% year over year growth in design wins underpins future revenue visibility and validates R&D investment strategy.
- Secular Tailwinds in Robotics and Medtech: Structural growth in automation and minimally invasive surgery support multi-year expansion, offsetting cyclicality in legacy industrial and life science markets.
- Margin Resilience Hinges on Tariff Mitigation: Regional manufacturing and cost reduction programs are essential to offset persistent tariff headwinds and support gross margin expansion.
- Acquisition-Driven Portfolio Shift: Keyon’s early outperformance and a deep M&A pipeline position Novanta to accelerate its transition toward software and recurring revenue models.
- Working Capital and Cash Flow Recovery: Inventory build and acquisition-related cash outflows are expected to normalize, but execution on inventory and tax management will be closely watched.
Risks
Tariff uncertainty and global trade disruptions remain a persistent risk, with $35 million in China-related revenue still at risk pending manufacturing transfers. Macroeconomic volatility, weak life science funding, and slow semiconductor upcycle could further pressure legacy segments. Execution risk around regionalization, cost reduction, and M&A integration could impact margin and growth targets if not managed tightly.
Forward Outlook
For Q3 2025, Novanta guided to:
- Revenue of $244 million to $247 million, flat to up 1% year over year
- Adjusted gross margin near 46%, with continued tariff and regionalization headwinds
- Adjusted EBITDA of $57 million to $60 million
- EPS of $0.78 to $0.85
For full-year 2025, management reaffirmed:
- Revenue of $970 million to $985 million (2% to 4% growth)
- Adjusted EBITDA of $225 million to $230 million (7% to 10% growth)
- EPS of $3.22 to $3.36 (5% to 9% growth)
Leadership emphasized continued strength in advanced surgery and robotics, sequential improvement in industrial and precision medicine, and a focus on executing regional manufacturing and M&A plans.
- Tariff mitigation and cost actions are expected to drive margin recovery by Q4
- Acquisition pipeline expected to yield at least one transaction by year end
Takeaways
Novanta’s Q2 call validated its pivot to innovation-led, secular growth markets, with bookings and design wins supporting a multi-year expansion thesis. Margin resilience will depend on the pace and success of regional manufacturing and cost actions, while portfolio transformation hinges on disciplined M&A execution.
- Growth Engine: Advanced surgery and physical AI robotics are driving visibility and outsized growth, with platform wins and OEM stickiness underpinning the outlook.
- Legacy Headwinds Moderating: Industrial and precision medicine segments are stabilizing, with sequential improvement expected as technology transitions take hold.
- Execution Watchpoints: Investors should monitor progress on tariff mitigation, regional manufacturing, and the timing and integration of new acquisitions as key drivers of margin and portfolio evolution.
Conclusion
Novanta’s Q2 2025 results showcased a business executing on a strategic transition, leveraging innovation and customer intimacy to capture secular growth in medtech and automation. With cost actions, regionalization, and M&A set to accelerate, the company is building a foundation for sustainable, margin-accretive growth despite persistent macro and trade headwinds.
Industry Read-Through
Novanta’s momentum in physical AI and advanced surgery signals accelerating demand for robotics, sensing, and intelligent subsystems across industrial and healthcare end markets. The success of regional manufacturing and “China for China” strategies offers a playbook for peers facing trade volatility. The rapid shift toward recurring consumables and software-rich solutions highlights a broader industry trend toward stickier, higher-margin business models. Life science and semiconductor suppliers should note the impact of funding and regulatory headwinds, but also the opportunity in next-gen technologies like RFID and machine vision.